How to Determine Medical Device Classification for Overseas Registration of Medical Dressings?

Key Summary

A practical guide for manufacturers, distributors, and regulatory teams on how to correctly classify medical dressings for overseas registration. Covers key classification logic, evidence requirements, common pitfalls, and a preparation checklist, followed by AIMEILI's regulatory interpretation and business impact anal

Executive Summary

The first step for medical dressings entering overseas markets is not preparing documentation, but accurately determining the medical device classification in the target country. Classification determines the registration pathway, depth of technical documentation, quality management system requirements, clinical evaluation level, and post-market surveillance obligations. Companies should first confirm whether the product qualifies as a medical device under the target country's legal framework, then review the applicable classification rules. Major markets such as GHWP member countries, the European Union, the United States, Southeast Asia, and the Middle East each have their own classification frameworks. Classification must be based on the product's intended use, mechanism of action, whether it contains drugs, whether it is sterile, and whether it has barrier functions, rather than relying solely on the common name.

Once classification is determined, companies can decide whether the manufacturer can self-register, submit through a local agent or authorized representative, or require a foreign certificate holder. For documentation, it is advisable to assess whether existing documents such as NMPA registration certificates, CE certificates, FDA clearances, ISO 13485 certificates, and MDSAP certificates can be reused. However, it is essential to distinguish which technical files can be directly converted and which must be rewritten to meet local language and regulatory requirements. Common risks include misclassification leading to incorrect registration pathways, inappropriate intended-use descriptions causing the product to be considered a drug-device combination, sterile dressings lacking biocompatibility evidence, labels and instructions not meeting local language requirements, and applications rejected due to failure to appoint a local agent. Companies should complete a classification pre-assessment before project initiation, establish a documentation matrix, and consult regulatory advisors with local experience to reduce rework and deficiency risks.

Applicable Scenarios and Core Issues

Medical dressings are a common category in medical device exports, including wound dressings, surgical dressings, adhesive bandages, alginate dressings, hydrocolloid dressings, foam dressings, and silver-containing dressings. Management approaches vary significantly across countries. Companies often reference the domestic Class II medical device pathway simply because the product is called a 'dressing,' leading to classification errors in overseas registration.

This article applies to manufacturers, exporters, and CROs planning to register medical dressings in GHWP member countries, the European Union, the United States, Southeast Asia, the Middle East, Latin America, and other markets. The core issue is how to accurately determine the classification level of medical dressings based on product attributes, intended use, and local regulations, and then plan the registration pathway and documentation accordingly.

Classification Decision Logic

Step 1: Confirm whether the product falls within the legal definition of a medical device in the target country. This includes whether the product is for human use, whether the primary intended use is achieved by physical means, and whether it has any pharmacological or metabolic action.

Step 2: Determine the risk class and corresponding registration pathway. Under the EU MDR, for example, non-invasive wound dressings are generally Class I, but if the product is intended for wounds that breach the dermis, or is claimed to be absorbable, or contains an active substance, it may be upgraded to Class IIa or IIb. The US FDA may classify such products as Class I (e.g., ordinary wound dressings) or Class II (e.g., silver-containing dressings), potentially requiring a 510(k). Southeast Asian and Latin American markets also have their own classification lists.

Step 3: Confirm the applicant entity and representative arrangements. Most countries require overseas manufacturers to appoint a local agent or authorized representative responsible for communication with regulatory authorities and receiving post-market safety notifications. Different classification levels may impose different requirements for the agent and the format of authorization documents.

Step 4: Evaluate whether existing documentation can be reused. If the product already holds an NMPA registration certificate, CE certificate, or FDA clearance, relevant test reports, quality management system certificates, and clinical data can serve as a basis. However, attention must be paid to differences in language, standards, and test methods. For instance, biocompatibility testing must comply with ISO 10993 series, but different countries may require GLP certification or local laboratory data.

Step 5: Confirm technical documentation, performance validation, risk management, clinical evaluation or clinical evidence, labeling and instructions for use, local agent, authorized representative, and post-market surveillance requirements. These elements should be refined after classification is established.

For GHWP member countries and multi-country registration scenarios, it is recommended to prepare a core set of technical documents and then perform local conversion according to each country's requirements. Classification reasoning should adopt a multi-country common logic where possible to avoid creating a separate system for each country.

Documentation and Evidence

Classification determination must be supported by evidence, not just experience. Companies should prepare the following materials to substantiate product classification and attributes:

Instructions for use, labeling, and packaging markings to confirm intended use and target population.
Product structure, material composition, and mechanism of action descriptions to determine whether the product is a drug-device combination or contains active substances.
Physical and chemical performance test reports, such as tensile strength, absorbency, and water vapor transmission rate.
Biocompatibility test reports, including cytotoxicity, sensitization, irritation, or intracutaneous reactivity.
Sterilization validation reports (if the product is supplied sterile), including sterilization method and sterility assurance level (SAL).
Risk management documentation, including risk analysis, risk evaluation, and risk control measures.
Clinical evaluation reports or clinical data summaries, especially for dressings with claimed efficacy.
Quality management system certificates, such as ISO 13485 or MDSAP, along with evidence of product scope coverage.

These documents serve as the basis for classification review. Regulatory authorities will focus on intended use and product mechanism when assessing classification. If a product claims to 'promote wound healing,' 'antibacterial,' or 'pain relief,' the risk class is typically raised.

Companies should also prepare a classification rationale document that explains why the product falls into a particular class, citing the target country's regulations and guidelines. This document should ideally be reviewed by a local advisor before submission.

Common Mistakes

Using domestic classification to determine overseas classification, ignoring local classification rules and product definition differences.
Writing overly broad intended-use statements, such as 'for all types of wounds,' leading regulators to require a higher level of clinical evidence.
Overlooking drug-device combination issues; dressings containing silver, iodine, antibiotics, or other active ingredients are filed as ordinary dressings.
Failing to separately describe sterilization method and sterility assurance for sterile dressings; some markets require additional validation for sterile products.
Directly translating labels and instructions without adjusting for local language, units, and regulatory requirements, causing deficiencies.
Ignoring the need for a valid local agent or authorized representative authorization document, leading to rejection or delay.
Reusing test reports without checking test standard versions and laboratory qualifications, resulting in retesting requirements.
Copying domestic templates for post-market surveillance plans without aligning with local post-market reporting obligations.

Company Preparation Checklist

Establish a multi-country product line list, noting the proposed product name and intended use in each target market.
Review classification rules for each country or region, and apply for a formal classification determination from local regulatory authorities when necessary.
Organize existing registration certificates, test reports, and quality management system certificates, and assess their validity and coverage.
Supplement biocompatibility, sterilization, and physical/chemical performance test reports based on product characteristics.
Prepare a classification rationale document and registration strategy, clearly defining the pathway (e.g., self-declaration, declaration of conformity, notification, or registration approval).
Designate or confirm a local agent/authorized representative, and prepare the authorization letter and contact details.
Draft and translate labels and instructions for use into local languages, ensuring compliance with local regulations.
Develop a post-market surveillance plan, including adverse event reporting, vigilance systems, and annual update requirements.
Establish a technical file update mechanism to ensure that product changes are promptly assessed for impact on registration.
For multi-country registration, create a common technical document library and make incremental modifications based on country-specific differences.

AIMEILI Regulatory Interpretation and Business Impact

Regulatory Interpretation: The most frequent misjudgment is focusing only on the product management category without reasoning backward from intended use and mechanism of action. We have encountered many clients who filed silver-containing dressings as ordinary Class II products and later faced additional clinical evaluation or reclassification overseas. It is strongly recommended to conduct a classification pre-review early in the project. The cost is minimal compared to the significant rework and delays that misclassification can cause.

Business Impact: Before initiating registration, it is essential to organize existing documentation and build a reusable matrix of NMPA registration certificates, CE technical files, FDA documents, and other regulatory approvals. Test reports and quality management system certificates are often reusable, but labeling, clinical evaluation summaries, and local agent arrangements must be localized. In particular, the EU MDR and several Southeast Asian countries are increasingly strict about clinical data and local clinical evaluations. Local agent and certificate control are critical for multi-country registration. Some countries require the local representative to hold the certificate, so companies must sign authorization agreements in advance and clearly define responsibilities. If changes and renewals are not handled promptly, certificates may lapse, resulting in products being held at customs. For multi-country registration, adopt a 'core technical file plus country-specific addenda' structure to reduce duplication and deficiency risk. We typically help clients establish a 'common + specific' document architecture, enabling rapid generation of compliant documents when adding new countries.

Frequently Asked Questions

How do you determine classification for medical dressings under the EU MDR?

Under the EU MDR, non-invasive wound dressings are generally classified as Class I. However, if the product is intended for wounds that breach the dermis, or is claimed to promote wound healing, or has claimed antimicrobial properties, it may be elevated to Class IIa. If the product contains a substance that is a drug or active substance, it may be managed as a drug-device combination. The classification rules are detailed in Annex VIII of the MDR and must be checked against each intended use.

What if the same dressing has different classifications in the US and Southeast Asia?

Different countries have independent classification systems, but in most cases they are similar. If classification differences arise, it is recommended to prepare documentation based on the higher risk class and to develop a separate classification rationale for each country. For example, the US FDA may classify a silver-containing dressing as Class II requiring a 510(k), while some Southeast Asian countries may manage it under a lower risk level, but local requirements must still be followed.

How can a classification error be corrected?

If the registration application has not yet been submitted, you can re-strategize and supplement the documentation. If it has already been submitted, you may need to withdraw the application or wait for feedback from the regulatory authority and then respond to deficiencies. Some countries allow classification dispute requests, but the process is time-consuming. It is strongly recommended to have a formal classification review by a local regulatory advisor before submission.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI